BUSINESS

Opdivo Extends OS in Second-Line Esophageal Cancer

January 10, 2019
Ono Pharmaceutical said on January 9 its anti-PD-1 antibody Opdivo (nivolumab) demonstrated a statistically significant extension in overall survival (OS) versus chemotherapy in a PIII study examining the drug as a second-line treatment for esophageal cancer. The global multi-center, randomized,…

To read the full story

BUSINESS

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

The Japanese cost-effectiveness assessment (CEA) scheme should be applied not only to the price adjustments of drugs and medical devices…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Reiji Anasako

With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…

By Tatsuya Otsuka

Driven by changes surrounding the Japanese generic drug market, generic companies are trying to shift from a “generic” to a “specialty” model for their main business, with more and more players steering their focus towards specialized areas to secure profits.The…

By Yoshinori Sagehashi

It’s official. Japan has decided to move ahead with the introduction of a cost-effectiveness assessment (CEA) scheme in April. But people from all walks of life – industry, government officials and academics included - are wondering, “What about the cost…